1
|
Rodak A, Stadlbauer K, Bobbili MR, Smrzka O, Rüker F, Wozniak Knopp G. Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells. Int J Mol Sci 2023; 24:14997. [PMID: 37834445 PMCID: PMC10573690 DOI: 10.3390/ijms241914997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/05/2023] [Accepted: 10/07/2023] [Indexed: 10/15/2023] Open
Abstract
High numbers of membrane immunoglobulin E (IgE)-positive cells are characteristic of allergic conditions, atopic dermatitis, or IgE myeloma. Antibodies targeting the extracellular membrane-proximal domain of the membranous IgE-B-cell receptor (BCR) fragment can be used for specific depletion of IgE-BCR-positive cells. In this study, we derivatized such an antibody with a toxin and developed an antibody-drug conjugate (ADC) that showed strong cytotoxicity for an IgE-positive target cell line. Site-specific conjugation with maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl-auristatin E via a newly introduced single cysteine residue was used to prepare a compound with a drug-antibody ratio of 2 and favorable biophysical properties. The antibody was rapidly taken up by the target cells, showing almost complete internalization after 4 h of treatment. Its cytotoxic effect was potentiated upon cross-linking mediated by an anti-human IgG F(ab')2 fragment. Because of its fast internalization and strict target specificity, this antibody-drug conjugate presents a valuable starting point for the further development of an anti-IgE cell-depleting agent, operating by the combined action of receptor cross-linking and toxin-mediated cytotoxicity.
Collapse
Affiliation(s)
- Aleksandra Rodak
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Katharina Stadlbauer
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Madhusudhan Reddy Bobbili
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
- Ludwig Boltzmann Institute for Traumatology, The Research Centre in Cooperation with AUVA, Donaueschingenstraße 13, 1200 Vienna, Austria
| | - Oskar Smrzka
- Ablevia Biotech GmbH, Maria Jacobi Gasse 1, 1030 Vienna, Austria;
| | - Florian Rüker
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| | - Gordana Wozniak Knopp
- Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, 1190 Vienna, Austria; (A.R.); (K.S.); (M.R.B.); (F.R.)
| |
Collapse
|
2
|
Ling XJ, Wei JF, Zhu Y. Aiming to IgE: Drug development in allergic diseases. Int Immunopharmacol 2023; 121:110495. [PMID: 37348229 DOI: 10.1016/j.intimp.2023.110495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Accepted: 06/09/2023] [Indexed: 06/24/2023]
Abstract
The incidence of allergic disease significantly increases in recent decades, causing it become a major public health problem all over the world. The common allergic diseases such as allergic dermatitis, allergy rhinitis, allergic asthma and food allergy are mediated, at least in part, by immunoglobulin E (IgE), and so IgE acts as a central role in allergic diseases. IgE can interact with its high-affinity receptor (FcεRⅠ) which is primarily expressed on tissue-resident mast cells and circulating basophils, initiating intracellular signal transduction and then causing the activation and degranulation of mast cells and basophils. On the other hand, IgE interaction with its low-affinity receptor (CD23), can regulate various IgE-mediated immune responses including IgE-allergen complex presentation, IgE synthesis, the growth and differentiation of both B and T cells, and the secretion of pro-inflammatory mediators. With the deeper mechanism research for allergic diseases, new therapeutic strategies for interfering IgE are developed and receive a great attention. In this review, we summarize a current profile of therapeutic strategies for interfering IgE in allergic diseases. Besides, we suggest that targeting memory B cells (including long-lived plasma cells and (or) IgE+ memory B cells) may help to completely control allergic diseases, and highlight that the development of drugs synergistically aiming to multiple targets can be a better choice for improving treatment efficacy which results from allergic diseases as the systemic disorders caused by an impaired immune system.
Collapse
Affiliation(s)
- Xiao-Jing Ling
- Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Ji-Fu Wei
- Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
| | - Ying Zhu
- Department of Blood Transfusion, Ganzhou Key Laboratory of Anesthesiology, Anesthesia and Surgery Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
| |
Collapse
|
3
|
Kuo BS, Li CH, Chen JB, Shiung YY, Chu CY, Lee CH, Liu YJ, Kuo JH, Hsu C, Su HW, Li YF, Lai A, Ho YF, Cheng YN, Huang HX, Lung MC, Wu MS, Yang FH, Lin CH, Tseng W, Yang J, Lin CY, Tsai PH, Chang HK, Wang YJ, Chen T, Lynn S, Liao MJ, Wang CY. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest 2022; 132:157765. [PMID: 35912861 PMCID: PMC9337824 DOI: 10.1172/jci157765] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 06/14/2022] [Indexed: 01/08/2023] Open
Abstract
Over the last 2 decades, omalizumab is the only anti-IgE antibody that has been approved for asthma and chronic spontaneous urticaria (CSU). Ligelizumab, a higher-affinity anti-IgE mAb and the only rival viable candidate in late-stage clinical trials, showed anti-CSU efficacy superior to that of omalizumab in phase IIb but not in phase III. This report features the antigenic-functional characteristics of UB-221, an anti-IgE mAb of a newer class that is distinct from omalizumab and ligelizumab. UB-221, in free form, bound abundantly to CD23-occupied IgE and, in oligomeric mAb-IgE complex forms, freely engaged CD23, while ligelizumab reacted limitedly and omalizumab stayed inert toward CD23; these observations are consistent with UB-221 outperforming ligelizumab and omalizumab in CD23-mediated downregulation of IgE production. UB-221 bound IgE with a strong affinity to prevent FcԑRI-mediated basophil activation and degranulation, exhibiting superior IgE-neutralizing activity to that of omalizumab. UB-221 and ligelizumab bound cellular IgE and effectively neutralized IgE in sera of patients with atopic dermatitis with equal strength, while omalizumab lagged behind. A single UB-221 dose administered to cynomolgus macaques and human IgE (ε, κ)-knockin mice could induce rapid, pronounced serum-IgE reduction. A single UB-221 dose administered to patients with CSU in a first-in-human trial exhibited durable disease symptom relief in parallel with a rapid reduction in serum free-IgE level.
Collapse
Affiliation(s)
- Be-Sheng Kuo
- United BioPharma, Inc., Hsinchu, Taiwan.,UBI Asia, Hsinchu, Taiwan.,United Biomedical, Inc., Hauppauge, New York, USA
| | | | | | | | - Chia-Yu Chu
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - Chih-Hung Lee
- Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | | | | | - Cindy Hsu
- United BioPharma, Inc., Hsinchu, Taiwan
| | | | | | - Annie Lai
- United BioPharma, Inc., Hsinchu, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Chang Yi Wang
- United BioPharma, Inc., Hsinchu, Taiwan.,UBI Asia, Hsinchu, Taiwan.,United Biomedical, Inc., Hauppauge, New York, USA
| |
Collapse
|
4
|
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006-1018. [PMID: 33966304 DOI: 10.1111/cea.13897] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 04/29/2021] [Accepted: 04/30/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Food allergy continues to pose problems due to its increased frequency and its increasingly high severity. In this context, alongside the traditional avoidance strategies of allergenic foods and desensitization through the cautious progression of exposure to foods in the context of oral immunotherapy (OIT), alternative strategies have made their way in the last decades. We review the possibilities of intervention in food allergy with the use of biological drugs capable of interfering with the synthesis of IgE, with their mechanisms of action, or with complex biological mechanisms that lead to the establishment of a food allergy. METHODS Repeated Entrez PubMed searches using the template algorithm "Food allergy" and "biologics" or "Omalizumab" or "Dupilumab" or "milk desensitization" or "oral tolerance induction" or "oral immunotherapy" or "Etokimab" or "Tezepelumab" or "Quilizumab" or "Ligelizumab" or "Tralokinumab" or "Nemolizumab" or "Mepolizumab" or "Reslizumab" or "Benralizumab". The authors' clinical experience in paediatric allergy units of University hospitals was also drawn upon. RESULTS The landscape in this context has changed dramatically over the past 10 years. We have acquired knowledge mainly on the effect of different types of anti-IgE treatments in poliallergic patients with food allergy, and in patients treated with OIT. However, other mediators are being targeted by specific biologic treatments. Among them, the alarmins Il-33 and TSLP, IL-4 and IL-13, eosinophil-related molecules as IL-6, IL-8, IL-10, IL-12, and mostly IL-5, and integrins involved in the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), as SIGLEC-8. CONCLUSIONS The ever-better knowledge of the mechanisms of food allergy allowing these developments will improve not only the perspective of patients with the most serious immediate food allergies such as anaphylaxis, but also those of patients with related diseases such as atopic dermatitis, eosinophilic esophagitis, and EGIDs. Biologics are also intended to complement OIT strategies that have developed over the years.
Collapse
Affiliation(s)
| | | | - Robert A Wood
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
5
|
Abstract
About 20 years after the identification of immunoglobulin E (IgE) and its key role in allergic hypersensitivity reactions against normally harmless substances, scientists have started inventing strategies to block its pathophysiological activity in 1986. The initial concept of specific IgE targeting through the use of anti-IgE antibodies has gained a lot of momentum and within a few years independent research groups have reported successful generation of first murine monoclonal anti-IgE antibodies. Subsequent generation of optimized chimeric and humanized versions of these antibodies has paved the way for the development of therapeutic anti-IgE biologicals as we know them today. With omalizumab, there is currently still only one therapeutic anti-IgE antibody approved for the treatment of allergic conditions. Since its application is limited to the treatment of moderate-to-severe persistent asthma and chronic spontaneous urticaria, major efforts have been undertaken to develop alternative anti-IgE biologicals that could potentially be used in a broader spectrum of allergic diseases. Several new drug candidates have been generated and are currently assessed in pre-clinical studies or clinical trials. In this review, we highlight the molecular properties of past and present anti-IgE biologicals and suggest concepts that might improve treatment efficacy of future drug candidates.
Collapse
Affiliation(s)
- Pascal Guntern
- Graduate School of Cellular and Biomedical Sciences University of Bern Bern Switzerland
- Department of BioMedical Research University of Bern Bern Switzerland
- Department of Rheumatology, Immunology and Allergology University Hospital Bern Bern Switzerland
| | - Alexander Eggel
- Department of BioMedical Research University of Bern Bern Switzerland
- Department of Rheumatology, Immunology and Allergology University Hospital Bern Bern Switzerland
| |
Collapse
|
6
|
Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int 2020; 69:167-177. [PMID: 32067933 DOI: 10.1016/j.alit.2020.01.004] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Accepted: 01/08/2020] [Indexed: 12/14/2022] Open
Abstract
IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and introduced a new era for the management of severe allergic conditions. About 10 years of experience with omalizumab treatment for severe allergic asthma confirmed its effectiveness and safety, reducing symptoms, frequency of reliever use, and severe exacerbations in patients with intractable conditions. Omalizumab is particularly useful in childhood asthma, where atopic conditions often determine clinical courses of asthma. Recently, omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) with the fixed dose of 300 mg. Although the mechanisms underlying the actions of omalizumab in CSU are not fully clarified, nearly 90% of patients with CSU showed a complete or a partial response to omalizumab treatment. Furthermore, omalizumab is just approved for the treatment of severe Japanese cedar pollinosis (JC) based on the successful results of an add-on study of omalizumab for inadequately controlled severe pollinosis despite antihistamines and nasal corticosteroids. For proper use of omalizumab to treat severe JC, co-administration of antihistamines is necessary, while patients should meet the criteria including strong sensitization to Japanese cedar pollen (≥class 3) and poor control under standard treatment. In the management of severe allergic diseases using omalizumab, issues including cost and concerns about relapse after its discontinuation should be overcome. At the same time, possibilities for application to other intractable allergic diseases should be considered.
Collapse
|
7
|
Garzón-Ospina D, Buitrago SP. Igh locus structure and evolution in Platyrrhines: new insights from a genomic perspective. Immunogenetics 2019; 72:165-179. [PMID: 31838542 DOI: 10.1007/s00251-019-01151-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 11/20/2019] [Indexed: 12/17/2022]
Abstract
Non-human primates have been used as animal models because of their phylogenetic closeness to humans. However, the genetic differences between humans and non-human primates must be considered to select the appropriate animal models. Recently, New World monkeys (Platyrrhines) have generated a higher interest in biomedical research, especially in assessing vaccine safety and immunogenicity. Given the continued and renewed interest in Platyrrhines as biomedical models, it is a necessary to have a better and more complete understanding of their immune system and its implications for research. Immunoglobulins (Ig) are the main proteins that mediate humoral immunity. These proteins have evolved as part of an adaptive immune response system derived from ancient vertebrates. There are at least four Ig classes in Prosimians, whereas five have been reported in Catarrhines. Information on the structure and evolution of the loci containing immunoglobulin heavy chain constant genes (Igh) in Platyrrhines, however, is limited. Here, Igh loci were characterized in 10 Platyrrhines using the available whole genome sequences. Human and Macaca Igh loci were also assessed to compare them with their Platyrrhines counterparts. Differences in Igh locus structure were observed between Platyrrhines and Catarrhines. Noteworthy changes occur in the γ gene, which encodes a key Ig involved in organism defense that would favor protection after vaccination. The remarkable differences between the immunoglobulin proteins of Platyrrhines and Catarrhines warrant a cautionary message to biomedical researchers.
Collapse
Affiliation(s)
- Diego Garzón-Ospina
- Pgame - Population Genetics And Molecular Evolution, Fundación Scient, Carrera 16-3 # 35-41, Tunja, Boyacá, Colombia.
| | - Sindy P Buitrago
- Pgame - Population Genetics And Molecular Evolution, Fundación Scient, Carrera 16-3 # 35-41, Tunja, Boyacá, Colombia.
| |
Collapse
|
8
|
Aberumand B, Ellis AK. Asthma and the Biologics Revolution, Part 2: Failures and the Future Potential. Curr Treat Options Allergy 2019. [DOI: 10.1007/s40521-019-00233-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Abstract
Immunological disorders such as allergy, autoimmune diseases, auto-inflammatory syndromes and immunological deficiency syndromes are difficult to treat with chemical drugs. Recently, many monoclonal antibodies targeting various molecules including interleukin, tumor necrosis factor-α, cluster of differentiation, integrins, complement C5 and B lymphocyte stimulator are clinically available and give a hope to patients suffering from these intractable diseases. Here, we selected twenty-seven monoclonal antibodies approved by US FDA since 1997 and they are classified according to their target molecules. Although these biomedicines possessed some restrictions such as high cost and susceptible to infectious disease, these drawbacks can be overcome through cost-cutting innovations including biosimilars and careful monitoring. New targets are emerging rapidly and more effective biomedicines with acceptable side effects are in the pipeline for next decade.
Collapse
Affiliation(s)
- Seon Min Yoo
- Department of Pharmacology, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Seoul, 02447, Republic of Korea
| | - Sung Hyun Chung
- Department of Pharmacology, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Seoul, 02447, Republic of Korea.
| |
Collapse
|
10
|
Chen JB, Ramadani F, Pang MOY, Beavil RL, Holdom MD, Mitropoulou AN, Beavil AJ, Gould HJ, Chang TW, Sutton BJ, McDonnell JM, Davies AM. Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody. Sci Rep 2018; 8:11548. [PMID: 30069035 PMCID: PMC6070508 DOI: 10.1038/s41598-018-29664-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 07/16/2018] [Indexed: 11/09/2022] Open
Abstract
Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, from acutely bent to extended conformations, with allosteric communication between the distant FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.
Collapse
Affiliation(s)
- Jiun-Bo Chen
- Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
| | - Faruk Ramadani
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Marie O Y Pang
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Rebecca L Beavil
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma Protein Production Facility, London, United Kingdom
| | - Mary D Holdom
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Alkistis N Mitropoulou
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Andrew J Beavil
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Hannah J Gould
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
| | - Tse Wen Chang
- Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan
| | - Brian J Sutton
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom.
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
| | - James M McDonnell
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom.
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
| | - Anna M Davies
- King's College London, Randall Centre for Cell and Molecular Biophysics, London, SE1 1UL, United Kingdom.
- Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
| |
Collapse
|
11
|
Hu J, Chen J, Ye L, Cai Z, Sun J, Ji K. Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE + B cells. Clin Transl Allergy 2018; 8:27. [PMID: 30026908 PMCID: PMC6050685 DOI: 10.1186/s13601-018-0213-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 05/28/2018] [Indexed: 12/14/2022] Open
Abstract
Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE+ B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells.
Collapse
Affiliation(s)
- Jiayun Hu
- 1Department of Biochemistry and Molecular Biology, School of Medicine of Shenzhen University, Shenzhen, 518035 China.,2Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730 China
| | - Jiajie Chen
- 1Department of Biochemistry and Molecular Biology, School of Medicine of Shenzhen University, Shenzhen, 518035 China
| | - Lanlan Ye
- 1Department of Biochemistry and Molecular Biology, School of Medicine of Shenzhen University, Shenzhen, 518035 China
| | - Zelang Cai
- 1Department of Biochemistry and Molecular Biology, School of Medicine of Shenzhen University, Shenzhen, 518035 China
| | - Jinlu Sun
- 2Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730 China
| | - Kunmei Ji
- 1Department of Biochemistry and Molecular Biology, School of Medicine of Shenzhen University, Shenzhen, 518035 China
| |
Collapse
|
12
|
Welt RS, Welt JA, Kostyal D, Gangadharan YD, Raymond V, Welt S. Specificity and biologic activities of novel anti-membrane IgM antibodies. Oncotarget 2018; 7:74701-74723. [PMID: 27732950 PMCID: PMC5342696 DOI: 10.18632/oncotarget.12506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2016] [Accepted: 09/24/2016] [Indexed: 12/03/2022] Open
Abstract
The concept that the B-cell Receptor (BCR) initiates a driver pathway in lymphoma-leukemia has been clinically validated. Previously described unique BCR Ig-class-specific sequences (proximal domains (PDs)), are not expressed in serum Ig (sIg). As a consequence of sequence and structural differences in the membrane IgM (mIgM) μ-Constant Domain 4, additional epitopes distinguish mIgM from sIgM. mAbs generated to linear and conformational epitopes, restricted to mIgM and not reacting with sIgM, were generated despite the relative hydrophobicity of the PDm sequence. Anti-PD mAbs (mAb1, mAb2, and mAb3) internalize mIgM. Anti-mIgM mAb4, which recognizes a distinct non-ligand binding site epitope, mediates mIgM internalization, and in low-density cultures, growth inhibition, anti-clonogenic activity, and apoptosis. We show that mAb-mediated mIgM internalization generally does not interrupt BCR-directed cell growth, however, mAb4 binding to a non-ligand binding site in the mIgM PDm-μC4 domain induces both mIgM internalization and anti-tumor effects. BCR micro-clustering in many B-cell leukemia and lymphoma lines is demonstrated by SEM micrographs using these new mAb reagents. mAb4 is a clinical candidate as a mediator of inhibition of the BCR signaling pathway. As these agents do not bind to non-mIgM B-cells, nor cross-react to non-lymphatic tissues, they may spare B-cell/normal tissue destruction as mAb-drug conjugates.
Collapse
Affiliation(s)
- Rachel S Welt
- American Museum of Natural History, New York, NY, USA
| | | | | | | | - Virginia Raymond
- Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA.,Biogent, LLC., Armonk, NY, USA
| | - Sydney Welt
- Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA
| |
Collapse
|
13
|
Abstract
This article presents an overview of future uses for biologic therapies in the treatment of immunologic and allergic conditions. Discussion is centered on the use of existing therapies outside of their current indication or on new therapies that are close to approval. This information may help familiarize practicing allergists and immunologists with therapies they may soon encounter in their practice as well as help identify conditions and treatments that will require further study in the near future.
Collapse
Affiliation(s)
- Santhosh Kumar
- Division of Allergy and Immunology, Children's Hospital of Richmond, Virginia Commonwealth University, CHoR Pavilion, 5th Floor, 1000 East Broad Street, Richmond, VA 23298-0225, USA.
| | - Brant R Ward
- Division of Allergy and Immunology, Children's Hospital of Richmond, Virginia Commonwealth University, CHoR Pavilion, 5th Floor, 1000 East Broad Street, Richmond, VA 23298-0225, USA; Division of Rheumatology, Allergy, and Immunology, Virginia Commonwealth University, McGuire Hall, Room 4-115A, 1112 East Clay Street, Richmond, VA 23298-0263, USA; Department of Microbiology and Immunology, Virginia Commonwealth University, 1101 East Marshall Street, P.O. Box 980678, Richmond, VA 23298, USA
| | - Anne-Marie Irani
- Division of Allergy and Immunology, Children's Hospital of Richmond, Virginia Commonwealth University, CHoR Pavilion, 5th Floor, 1000 East Broad Street, Richmond, VA 23298-0225, USA
| |
Collapse
|
14
|
Vigl B, Salhat N, Parth M, Pankevych H, Mairhofer A, Bartl S, Smrzka OW. Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies. J Immunol Methods 2017. [PMID: 28647457 DOI: 10.1016/j.jim.2017.06.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair®) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Since tools to selectively assess the efficacy of IgE BCR crosslinking by IgE targeting antibodies are limited, a readily quantifiable cell model was developed that allows to specifically address IgE BCR crosslinking activity in vitro. The new cell model allowed for a direct quantitative comparison of anti-EMPD IgE therapeutic prototype antibody 47H4 with anti-IgE(Ce3) directed therapeutic antibody Omalizumab and with a newly selected anti-human EMPD IgE monoclonal antibody, designated mAB 15cl12. Furthermore, a complementing mouse model was developed that allows for in vivo validation of antibodies addressing human EMPD IgE. It carries a targetable humanized EMPD IgE sequence that has been introduced by seamless genomic replacement of the endogenous EMPD encoding sequence. The model allowed to directly compare IgE lowering activity of two anti-human EMPD IgE therapeutic antibodies in vivo. Our tools provide the means for quantitative assessment of IgE BCR crosslinking activity which is increasingly gaining attention with respect to forthcoming second generation anti-IgE clinical candidates such as Ligelizumab or other clinical candidates featuring additional effector functions such as IgE BCR crosslinking activity.
Collapse
Affiliation(s)
- Benjamin Vigl
- AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria.
| | - Nina Salhat
- AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria
| | - Michela Parth
- AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria
| | | | | | - Stefan Bartl
- AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria
| | | |
Collapse
|
15
|
Ramadani F, Bowen H, Upton N, Hobson PS, Chan YC, Chen JB, Chang TW, McDonnell JM, Sutton BJ, Fear DJ, Gould HJ. Ontogeny of human IgE-expressing B cells and plasma cells. Allergy 2017; 72:66-76. [PMID: 27061189 PMCID: PMC5107308 DOI: 10.1111/all.12911] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/05/2016] [Indexed: 12/31/2022]
Abstract
Background IgE‐expressing (IgE+) plasma cells (PCs) provide a continuous source of allergen‐specific IgE that is central to allergic responses. The extreme sparsity of IgE+ cells in vivo has confined their study almost entirely to mouse models. Objective To characterize the development pathway of human IgE+PCs and to determine the ontogeny of human IgE+PCs. Methods To generate human IgE+ cells, we cultured tonsil B cells with IL‐4 and anti‐CD40. Using FACS and RT‐PCR, we examined the phenotype of generated IgE+ cells, the capacity of tonsil B‐cell subsets to generate IgE+PCs and the class switching pathways involved. Results We have identified three phenotypic stages of IgE+PC development pathway, namely (i) IgE+germinal centre (GC)‐like B cells, (ii) IgE+PC‐like ‘plasmablasts’ and (iii) IgE+PCs. The same phenotypic stages were also observed for IgG1+ cells. Total tonsil B cells give rise to IgE+PCs by direct and sequential switching, whereas the isolated GC B‐cell fraction, the main source of IgE+PCs, generates IgE+PCs by sequential switching. PC differentiation of IgE+ cells is accompanied by the down‐regulation of surface expression of the short form of membrane IgE (mIgES), which is homologous to mouse mIgE, and the up‐regulation of the long form of mIgE (mIgEL), which is associated with an enhanced B‐cell survival and expressed in humans, but not in mice. Conclusion Generation of IgE+PCs from tonsil GC B cells occurs mainly via sequential switching from IgG. The mIgEL/mIgES ratio may be implicated in survival of IgE+ B cells during PC differentiation and allergic disease.
Collapse
Affiliation(s)
- F. Ramadani
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - H. Bowen
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - N. Upton
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - P. S. Hobson
- Division of Asthma; Allergy and Lung Biology; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - Y.-C. Chan
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - J.-B. Chen
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - T. W. Chang
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - J. M. McDonnell
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - B. J. Sutton
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - D. J. Fear
- Division of Asthma; Allergy and Lung Biology; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| | - H. J. Gould
- Randall Division of Cell and Molecular Biohphysics; King's College; London UK
- Medical Research Council and Asthma UK Centre in Allergic Mechanisms in Asthma; London UK
| |
Collapse
|
16
|
Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J Immunol Res 2016; 2016:8163803. [PMID: 28097159 DOI: 10.1155/2016/8163803] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 11/02/2016] [Indexed: 12/23/2022] Open
Abstract
IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcε receptor I complex.
Collapse
|
17
|
Affiliation(s)
- Roopesh Singh Gangwar
- Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | - Nadine Landolina
- Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | - Ludovica Arpinati
- Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
| | - Francesca Levi-Schaffer
- Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.
| |
Collapse
|
18
|
Chen JB, James LK, Davies AM, Wu YCB, Rimmer J, Lund VJ, Chen JH, McDonnell JM, Chan YC, Hutchins GH, Chang TW, Sutton BJ, Kariyawasam HH, Gould HJ. Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2016; 139:1195-1204.e11. [PMID: 27658758 PMCID: PMC5380656 DOI: 10.1016/j.jaci.2016.06.066] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 05/07/2016] [Accepted: 06/13/2016] [Indexed: 01/19/2023]
Abstract
Background Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyperproduction and the presence of IgE antibodies against Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-SAEs. Objectives We aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (CDRs) or framework regions. Methods Labeled staphylococcal enterotoxin (SE) A, SED, and SEE were used to isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated respiratory disease by using fluorescence-activated cell sorting. Recombinant antibodies with “matched” heavy and light chains were cloned as IgG1, and those of high affinity for specific SAEs, assayed by means of ELISA and surface plasmon resonance, were recloned as IgE and antigen-binding fragments. IgE activities were tested in basophil degranulation assays. Results Thirty-seven SAE-specific, IgG- or IgA-expressing B cells were isolated and yielded 6 anti-SAE clones, 2 each for SEA, SED, and SEE. Competition binding assays revealed that the anti-SEE antibodies recognize nonoverlapping epitopes in SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation, and IgG1 or antigen-binding fragments of each anti-SEE enhanced degranulation by the other anti-SEE. Conclusions SEEs can activate basophils by simultaneously binding as antigens in the conventional manner to CDRs and as superantigens to framework regions of anti-SEE IgE in anti-SEE IgE-FcεRI complexes. Anti-SEE IgG1s can enhance the activity of anti-SEE IgEs as conventional antibodies through CDRs or simultaneously as conventional antibodies and as “superantibodies” through CDRs and framework regions to SEEs in SEE–anti-SEE IgE-FcεRI complexes.
Collapse
Affiliation(s)
- Jiun-Bo Chen
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Louisa K James
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - Anna M Davies
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - Yu-Chang Bryan Wu
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - Joanne Rimmer
- Allergy and Rhinology, Royal National Throat Nose Ear Hospital, London, United Kingdom
| | - Valerie J Lund
- Allergy and Rhinology, Royal National Throat Nose Ear Hospital, London, United Kingdom
| | - Jou-Han Chen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - James M McDonnell
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - Yih-Chih Chan
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - George H Hutchins
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom
| | - Tse Wen Chang
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Brian J Sutton
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom
| | - Harsha H Kariyawasam
- Allergy and Rhinology, Royal National Throat Nose Ear Hospital, London, United Kingdom
| | - Hannah J Gould
- Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom; MRC & Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Campus, London, United Kingdom.
| |
Collapse
|
19
|
Liour SS, Tom A, Chan YH, Chang TW. Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody. Pediatr Allergy Immunol 2016; 27:446-51. [PMID: 27090058 DOI: 10.1111/pai.12584] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/17/2016] [Indexed: 01/17/2023]
Abstract
Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcεRI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti-IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others. Anti-CεmX, which binds to membrane-bound IgE (mIgE) on IgE-switched B cells, lyses mIgE-expressing B lymphoblasts and prevents the allergen-induced generation of IgE-producing plasma cells, offers an alternative mechanism of intervening with the IgE inflammatory pathway. Because anti-CεmX does not bind to free IgE, it can modulate the IgE pathway regardless of the serum IgE levels in treated patients. These unique pharmacologic mechanisms potentially enable anti-CεmX to provide different clinical utilities from anti-IgE and serve as a therapeutic and a prophylactic in some IgE-mediated diseases, which are not adequately treated with current medicine.
Collapse
Affiliation(s)
| | - Andrew Tom
- Genomics Research Center, Taipei, Taiwan
| | | | | |
Collapse
|
20
|
Landolina N, Levi-Schaffer F. Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol 2016; 173:793-803. [PMID: 26620589 DOI: 10.1111/bph.13396] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Revised: 11/08/2015] [Accepted: 11/22/2015] [Indexed: 12/18/2022] Open
Abstract
Allergic diseases and conditions are widespread and their incidence is on the increase. They are characterized by the activation of mast cells resident in tissues and the consequent infiltration and stimulation of several inflammatory cells, predominantly eosinophils. Cell-cell cross-talk and the release of mediators are responsible for the symptoms and for the modulation of the response. The gold standard of therapeutic intervention is still glucocorticosteroids, although they are not effective in all patients and may cause numerous side effects. Symptomatic medications are also widespread. As research has led to deeper insights into the mechanisms governing the diseases, new avenues have been opened resulting in recent years in the development of monoclonal antibodies (mAbs) such as anti-IgE mAbs (omalizumab) and others still undergoing clinical trials aimed to specifically target molecules involved in the migration and stimulation of inflammatory cells. In this review, we summarize new developments in the field of anti-allergic mAbs with special emphasis on the treatment of asthma, particularly severe forms of this condition, and atopic dermatitis, which are two unmet clinical needs.
Collapse
Affiliation(s)
- N Landolina
- Pharmacology and Experimental Therapeutics Unit, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - F Levi-Schaffer
- Pharmacology and Experimental Therapeutics Unit, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| |
Collapse
|
21
|
Ramadani F, Upton N, Hobson P, Chan YC, Mzinza D, Bowen H, Kerridge C, Sutton BJ, Fear DJ, Gould HJ. Intrinsic properties of germinal center-derived B cells promote their enhanced class switching to IgE. Allergy 2015; 70:1269-77. [PMID: 26109279 PMCID: PMC4744720 DOI: 10.1111/all.12679] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/18/2015] [Indexed: 02/03/2023]
Abstract
Background Research on the origins and development of human IgE‐expressing (IgE+) cells is required for understanding the pathogenesis of allergy and asthma. These studies have been thwarted by the rarity of IgE+ cells in vivo and the low frequency of class switch recombination (CSR) to IgE ex vivo. To determine the main source of IgE+ cells, we investigated the relation between the phenotypic composition of tonsil B cells and the CSR to IgE ex vivo. Methods Human tonsil B cells were analyzed by flow cytometry (FACS) and cultured with IL‐4 and anti‐CD40 to induce CSR to IgE. Naïve, germinal center (GC), early GC (eGC), and memory tonsil B cells were isolated by FACS, and their capacities for IL‐4 and anti‐CD40 signaling, cell proliferation, and de novo class switching to IgE were analyzed by RT‐PCR and FACS. Results B cells from different tonsils exhibited varying capacities for CSR to IgE ex vivo. This was correlated with the percentage of eGC B cells in the tonsil at the outset of the culture. Despite relatively poor cell viability, eGC and GC B‐cell cultures produced the highest yields of IgE+ cells compared to naïve and memory B‐cell cultures. The main factors accounting for this result were the strength of IL‐4R and CD40 signaling and relative rates of cell proliferation. Conclusions This study shows that the maturation state of tonsil B cells determines their capacity to undergo class switching to IgE ex vivo, with the GC‐derived B cells yielding the highest percentage of IgE+ cells.
Collapse
Affiliation(s)
- F. Ramadani
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - N. Upton
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - P. Hobson
- Division of Asthma, Allergy and Lung Biology; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - Y.-C. Chan
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - D. Mzinza
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - H. Bowen
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - C. Kerridge
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - B. J. Sutton
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - D. J. Fear
- Division of Asthma, Allergy and Lung Biology; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| | - H. J. Gould
- Randall Division of Cell and Molecular Biohphysics; King's College London; London UK
- Medical Research Council and Asthma UK Centre; Allergic Mechanisms in Asthma; London UK
| |
Collapse
|
22
|
Bauer RN, Manohar M, Singh AM, Jay DC, Nadeau KC. The future of biologics: applications for food allergy. J Allergy Clin Immunol 2015; 135:312-23. [PMID: 25662303 DOI: 10.1016/j.jaci.2014.12.1908] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Revised: 11/20/2014] [Accepted: 12/03/2014] [Indexed: 01/18/2023]
Abstract
Allergic diseases affect millions worldwide, with growing evidence of an increase in allergy occurrence over the past few decades. Current treatments for allergy include corticosteroids to reduce inflammation and allergen immunotherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to these treatments, and there are currently no approved therapeutics for the treatment of food allergy. There is a dire need for new therapeutic approaches for patients with poorly controlled atopic diseases and a need to improve the safety and effectiveness of allergen immunotherapy. Improved understanding of allergy through animal models and clinical trials has unveiled potential targets for new therapies, leading to the development of several biologics to treat allergic diseases. This review focuses on the mechanisms that contribute to allergy, with an emphasis on future targets for biologics for the treatment of food allergy. These biologics include immunotherapy with novel anti-IgE antibodies and analogs, small-molecule inhibitors of cell signaling, anti-type 2 cytokine mAbs, and TH1-promoting adjuvants.
Collapse
|
23
|
Lu CS, Hung AF, Lin CJ, Chen JB, Chen C, Shiung YY, Tsai CY, Chang TW. Generating allergen-specific human IgEs for immunoassays by employing human ε gene knockin mice. Allergy 2015; 70:384-90. [PMID: 25616164 DOI: 10.1111/all.12572] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND Antigen-specific human IgEs are important reagents in immunoassays to quantify antigen-specific IgEs in allergic patients, but they are not easy to prepare. METHODS We constructed a knockin homozygous mouse strain, referred to as HεκKI strain, whose gene segment encoding γ1 constant region has been replaced by that encoding human ε constant region and gene segment encoding κ constant region replaced by that encoding human κ constant region. The mice were tested for their ability to produce antigen-specific chimeric human IgE (with mouse variable regions) upon the immunization with ovalbumin and papain. Subsequently, the spleen cells from the immunized mice were used as the source of B cells for the preparation of hybridomas, which secreted monoclonal human IgE antibodies specific for the antigens. RESULTS The HεκKI mice expressed human IgE (ε, κ) in serum at levels 10- to 30-fold higher than those of mouse IgE. Upon immunization with an antigen, the mice yielded splenic B cells for preparing hybridomas that secrete chimeric human IgE specific for the antigen. Purified IgEs from those hybridomas could activate a basophilic cell line to undergo degranulation upon the stimulation with their respective antigens. CONCLUSIONS We have developed a human ε gene and κ gene knockin mouse strain, which is useful for producing various antigen-specific chimeric human IgEs for potential use as standards in immunoassays.
Collapse
Affiliation(s)
- C.-S. Lu
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - A. F. Hung
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - C.-J. Lin
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - J.-B. Chen
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - C. Chen
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - Y.-Y. Shiung
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| | - C.-Y. Tsai
- Institute of Molecular Biology; Academia Sinica; Taipei Taiwan
| | - T. W. Chang
- Genomics Research Center; Academia Sinica; Taipei Taiwan
| |
Collapse
|
24
|
Nyborg AC, Zacco A, Ettinger R, Jack Borrok M, Zhu J, Martin T, Woods R, Kiefer C, Bowen MA, Suzanne Cohen E, Herbst R, Wu H, Coats S. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol 2015; 13:391-400. [PMID: 25942513 PMCID: PMC4856805 DOI: 10.1038/cmi.2015.19] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/10/2015] [Accepted: 02/11/2015] [Indexed: 12/26/2022] Open
Abstract
Immunoglobulin E (IgE) plays a key role in allergic asthma and is a clinically validated target for monoclonal antibodies. Therapeutic anti-IgE antibodies block the interaction between IgE and the Fc epsilon (Fcε) receptor, which eliminates or minimizes the allergic phenotype but does not typically curtail the ongoing production of IgE by B cells. We generated high-affinity anti-IgE antibodies (MEDI4212) that have the potential to both neutralize soluble IgE and eliminate IgE-expressing B-cells through antibody-dependent cell-mediated cytotoxicity. MEDI4212 variants were generated that contain mutations in the Fc region of the antibody or alterations in fucosylation in order to enhance the antibody's affinity for FcγRIIIa. All MEDI4212 variants bound to human IgE with affinities comparable to the wild-type (WT) antibody. Each variant was shown to inhibit the interaction between IgE and FcεRI, which translated into potent inhibition of FcγRI-mediated function responses. Importantly, all variants bound similarly to IgE at the surface of membrane IgE expressing cells. However, MEDI4212 variants demonstrated enhanced affinity for FcγRIIIa including the polymorphic variants at position 158. The improvement in FcγRIIIa binding led to increased effector function in cell based assays using both engineered cell lines and class switched human IgE B cells. Through its superior suppression of IgE, we anticipate that effector function enhanced MEDI4212 may be able to neutralize high levels of soluble IgE and provide increased long-term benefit by eliminating the IgE expressing B cells before they differentiate and become IgE secreting plasma cells.
Collapse
Affiliation(s)
| | | | | | | | - Jie Zhu
- MedImmune LLC, Gaithersburg, MD, USA
| | | | - Rob Woods
- MedImmune LLC, Gaithersburg, MD, USA
| | | | | | - E Suzanne Cohen
- MedImmune Ltd, Milstein Building, Granta Park, Cambridge, UK
| | | | - Herren Wu
- MedImmune LLC, Gaithersburg, MD, USA
| | | |
Collapse
|
25
|
Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 2015; 6:243ra85. [PMID: 24990880 DOI: 10.1126/scitranslmed.3008961] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Elevated serum levels of both total and allergen-specific immunoglobulin E (IgE) correlate with atopic diseases such as allergic rhinitis and allergic asthma. Neutralization of IgE by anti-IgE antibodies can effectively treat allergic asthma. Preclinical studies indicate that targeting membrane IgE-positive cells with antibodies against M1 prime can inhibit the production of new IgE and significantly reduce the levels of serum IgE. We report results from two trials that investigated the safety, pharmacokinetics, and activity of quilizumab, a humanized monoclonal antibody targeting specifically the M1 prime epitope of membrane IgE, in subjects with allergic rhinitis (NCT01160861) or mild allergic asthma (NCT01196039). In both studies, quilizumab treatment was well tolerated and led to reductions in total and allergen-specific serum IgE that lasted for at least 6 months after the cessation of dosing. In subjects with allergic asthma who were subjected to an allergen challenge, quilizumab treatment blocked the generation of new IgE, reduced allergen-induced early and late asthmatic airway responses by 26 and 36%, respectively, and reduced allergen-induced increases in sputum eosinophils by ~50% compared with placebo. These studies indicate that targeting of membrane IgE-expressing cells with anti-M1 prime antibodies can prevent IgE production in humans.
Collapse
Affiliation(s)
| | | | - Louis-Philippe Boulet
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Québec G1V 4G5, Canada
| | | | - J Mark Fitzgerald
- University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada
| | | | | | - Beth E Davis
- University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W8, Canada
| | - Richard Leigh
- University of Calgary, Calgary, Alberta T2N 4Z6, Canada
| | - Yanan Zheng
- Genentech Inc., South San Francisco, CA 94080, USA
| | - Barbro Dahlén
- Karolinska University Hospital, Stockholm S-141 86, Sweden
| | - Yehong Wang
- Genentech Inc., South San Francisco, CA 94080, USA
| | | | - Irvin Mayers
- University of Alberta, Edmonton, Alberta T6G 2G3, Canada
| | | | - Lawren C Wu
- Genentech Inc., South San Francisco, CA 94080, USA
| | | | | |
Collapse
|
26
|
Abstract
Survival and phenotype of normal and malignant B lymphocytes are critically dependent on constitutive signals by the B cell receptor (BCR) for antigen. In addition, either antigen ligation of the BCR or various mitogenic stimuli result in B cell activation and induction of activation-induced deaminase (AID). AID activity can in turn mediate somatic hypermutation (SHM) of immunoglobulin (Ig) V regions and also deeply remodel the Ig heavy chain locus through class switch recombination (CSR) or locus suicide recombination (LSR). In addition to changes linked to affinity for antigen, modifying the class/isotype (i.e. the structure and function) of the BCR or suddenly deleting BCR expression also modulates the fate of antigen-experienced B cells.
Collapse
|
27
|
Wu LC, Scheerens H. Targeting IgE production in mice and humans. Curr Opin Immunol 2014; 31:8-15. [PMID: 25156315 DOI: 10.1016/j.coi.2014.08.001] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Revised: 08/01/2014] [Accepted: 08/04/2014] [Indexed: 11/26/2022]
Abstract
Immunoglobulin E (IgE) is pathogenic in allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, and food allergy. Recent studies using genetically modified IgE reporter mice indicate that the majority of serum IgE in mice is produced by short-lived IgE plasma cells, with minor contributions from long-lived IgE plasma cells, and implicate IgG1 and IgE memory B cells as potential sources of IgE memory. Clinical studies using antibodies against IL-13 or the IL-4 and IL-13 receptor subunit IL-4Rα, as well as an antibody against the M1 prime domain of human membrane IgE, indicate that, similar to mice, a proportion of IgE in humans is derived from ongoing IgE immune responses and short-lived plasma cells. Targeting IgE production may lead to new therapies for the treatment of allergic diseases.
Collapse
Affiliation(s)
- Lawren C Wu
- Department of Immunology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
| | - Heleen Scheerens
- Department of Pharmacodynamic Biomarkers, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
| |
Collapse
|
28
|
Chu H, Wright J, Chan Y, Lin C, Chang TW, Lim C. Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations. Nat Commun 2014; 5. [DOI: 10.1038/ncomms4139] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 12/17/2013] [Indexed: 11/09/2022] Open
|
29
|
Chang TW, Chen J, Chu C. The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis. DERMATOL SIN 2012; 30:147-53. [DOI: 10.1016/j.dsi.2012.10.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
30
|
Chowdhury PS, Chen Y, Yang C, Cook KE, Nyborg AC, Ettinger R, Herbst R, Kiener PA, Wu H. Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol 2012; 52:279-88. [DOI: 10.1016/j.molimm.2012.06.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Revised: 05/16/2012] [Accepted: 06/04/2012] [Indexed: 11/28/2022]
|
31
|
Lin C, Chen N, Chen J, Lu C, Hung AF, Shiung Y, Wu PC, Pan R, Chang TW. CɛmX peptide-carrying HBcAg virus-like particles induced antibodies that down-regulate mIgE-B lymphocytes. Mol Immunol 2012; 52:190-9. [DOI: 10.1016/j.molimm.2012.05.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Revised: 05/21/2012] [Accepted: 05/21/2012] [Indexed: 10/28/2022]
|
32
|
Chen NY, Hung AFH, Lin CJ, Chen JB, Chu HM, Yu HM, Chang HY, Chang TW. Manipulating mIgD-expressing B cells with anti-migis-δ monoclonal antibodies. Mol Immunol 2012; 53:187-97. [PMID: 22944457 DOI: 10.1016/j.molimm.2012.08.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Revised: 07/31/2012] [Accepted: 08/07/2012] [Indexed: 11/18/2022]
Abstract
Surface IgD and IgM doubly positive cells comprise the major population of B cells in the human immune system. The heavy chain of membrane-bound IgD (mδ) differs from that of IgD (δ) in that mδ contains a C-terminal membrane-anchor peptide. Our group previously proposed that the N-terminal extracellular segment of 27 aa residues of the membrane-anchor peptide of mδ, referred to as the mIg isotype-specific-δ (migis-δ) segment, may provide a unique antigenic site for isotype-specific targeting of mIgD(+) B cells. Here we report the preparation of mouse mAbs specific for human migis-δ. The mAbs bound to human migis-δ-containing recombinant proteins in an ELISA and to mIgD-expressing transfectants of a CHO cell line as analyzed by flow cytometry. MAb 20E6, which binds to an epitope toward the N-terminal of human migis-δ, could stain human B cell line MC116, which expressed mIgD and mIgM. MC116 cells could be induced to undergo apoptosis by treatment with 20E6 in the presence of a second crosslinking antibody. Chimeric 20E6 caused antibody-dependent cellular cytotoxicity of MC116 cells in the presence of human PBMCs as the source of effector cells. In cultures of PBMCs, 20E6 down-regulated the population of mIgD(+) B cells. The production of human IgM by transplanted MC116 cells in NOD-SCID (NOD.CB17-Prkdc(scid)/IcrCrlBltw) mice could be suppressed by 20E6. These results encourage further investigation of the potential of anti-migis-δ mAbs to control mIgD(+) B cells, when such a manipulation may alleviate a disease state.
Collapse
Affiliation(s)
- Nien-Yi Chen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan; Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Some 10 years ago it emerged that at sufficiently high concentrations certain monoclonal mouse IgEs exert previously unsuspected effects on mast cells. Thus they can both promote survival and induce activation of mast cells without the requirement for antigens. This was a wake up call that appears to have been missed (or dismissed) by the majority of immunologists. The structural attributes responsible for the potency of the so-called “highly cytokinergic” or HC IgEs have not yet been determined, but the events that ensue when such IgEs bind to the high-affinity receptor, FcεRI, on mast cells have been thoroughly studied, and are strikingly similar to those engendered by antigens when they form cross-linked complexes with the receptors. We review the evidence for the cytokinergic activity of IgE, and the structural features and known properties of immunoglobulins, and of IgE in particular, most likely to be implicated in the phenomenon. We suggest that IgEs with cytokinergic activity may be generated by local germinal center reactions in the target organs of allergy. We consider also the important implications that the existence of cytokinergic IgE may have for a fuller understanding of adaptive immunity and of the action of IgE in asthma and other diseases.
Collapse
Affiliation(s)
- Heather J Bax
- Randall Division of Cell and Molecular Biophysics, King's College London London, UK
| | | | | |
Collapse
|
34
|
Shiung YY, Chiang CY, Chen JB, Wu PC, Hung AFH, Lu DCS, Pan RL, Chang TW. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors. Immunobiology 2012; 217:676-83. [DOI: 10.1016/j.imbio.2011.11.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2011] [Accepted: 11/18/2011] [Indexed: 11/25/2022]
|
35
|
Dullaers M, De Bruyne R, Ramadani F, Gould HJ, Gevaert P, Lambrecht BN. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2011; 129:635-45. [PMID: 22168998 DOI: 10.1016/j.jaci.2011.10.029] [Citation(s) in RCA: 125] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Revised: 10/18/2011] [Accepted: 10/19/2011] [Indexed: 02/07/2023]
Abstract
Allergic asthma and allergic rhinitis/conjunctivitis are characterized by a T(H)2-dominated immune response associated with increased serum IgE levels in response to inhaled allergens. Because IgE is a key player in the induction and maintenance of allergic inflammation, it represents a prime target for therapeutic intervention. However, our understanding of IgE biology remains fragmentary. This article puts together our current knowledge on IgE in allergic airway diseases with a special focus on the identity of IgE-secreting cells ("who"), their location ("where"), and the circumstances in which they are induced ("when"). We further consider the therapeutic implications of the insights gained.
Collapse
Affiliation(s)
- Melissa Dullaers
- Laboratorium of Immunoregulation and Mucosal Immunology, Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
| | | | | | | | | | | |
Collapse
|
36
|
Wu PC, Chen JB, Kawamura S, Roos C, Merker S, Shih CC, Hsu BD, Lim C, Chang TW. The IgE gene in primates exhibits extraordinary evolutionary diversity. Immunogenetics 2012; 64:279-87. [PMID: 22068888 DOI: 10.1007/s00251-011-0586-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Accepted: 10/27/2011] [Indexed: 10/15/2022]
Abstract
Membrane-bound IgE (mIgE) on B lymphocytes is essential for IgE production. Earlier studies showed that the ε chain of mIgE (mε) on human B cells has a "long" isoform, with an extra "CεmX" domain of 52 amino acid (aa) residues between the CH4 domain and the membrane-anchor segment, as compared to the conventional "short" isoform. Because CεmX provides an antigenic site for targeting IgE-expressing B cells to down-regulate IgE production in patients with allergy, analysis of CεmX in various animals is of great interest. Hence, we analyzed the ε Ig gene, in particular, its membrane exon regions encoding the membrane anchor peptide segment and CεmX domain, of 26 species of the order Primates and 12 species of seven non-Primate orders using data obtained experimentally or retrieved from GenBank. Our analyses reveal the unexpected finding that the genes of three extant tarsier species do not contain the membrane exons for mIgE. Another striking finding is that early evolved Strepsirhini primates such as lemurs and lorises do not have gene segments for the long isoform, whereas New World monkeys such as marmosets and squirrel monkeys allow the transcription of only the long isoform. In Old World monkeys and apes, including humans, the ε gene allows the transcription of both isoforms. This work thus reveals the dramatic differences in the gene segment encoding the mε C terminal region among the four major primate lineages: the Strepsirhini primates, the tarsiers, New World monkeys, and Old World monkeys and apes/humans.
Collapse
|
37
|
Hung AFH, Chen JB, Lu CS, Chen NY, Yu HM, Chang TW. Lipid rafts hinder binding of antibodies to the extracellular segment of the membrane-anchor peptide of mIgA. Mol Immunol 2011; 48:1975-82. [PMID: 21723611 DOI: 10.1016/j.molimm.2011.06.219] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2011] [Revised: 06/01/2011] [Accepted: 06/04/2011] [Indexed: 10/18/2022]
Abstract
Membrane-bound IgA (mIgA) is associated with Igα/Igβ as the B cell receptor (BCR) complex on mIgA-expressing B cells. The α chain of mIgA (mα) contains a C-terminal membrane-anchor peptide, which encompasses extracellular, transmembrane and intracellular segments. The extracellular segment, referred to as the mIg isotype-specific (migis-α) segment or the extracellular membrane proximal domain of mα, has been proposed to be a specific antigenic site suitable for isotype-specific targeting of mIgA-expressing B cells by antibodies. In this study, we developed several anti-migis-α monoclonal antibodies (mAbs), such as mAb 29C11, specific to a segment towards the N-terminus of the 26 amino acid long migis-α. The mAbs bound strongly to synthetic peptides of migis-α and to various recombinant proteins containing migis-α as revealed by ELISA. On B cells, however, flow cytometric analysis suggested that these mAbs did not bind strongly to mIgA. After lipid rafts of B cells were disrupted by cholesterol extraction, the mAbs were able to bind strongly to the treated B cells. Moreover, immunoprecipitation analysis of these mAbs indicated that mIgA could only be pulled down by the mAbs when mIgA-expressing B cells were solubilized by strong detergents, such as sodium dodecyl sulfate (SDS), or when lipid rafts were disrupted. Together, these results suggest that the migis-α region of mIgA in the BCR is associated with lipid rafts, which hinder binding of migis-α-specific antibodies to mIgA on the cell surface. Further studies are in progress to evaluate the suitability of 29C11 or its affinity-improved variants for targeting mIgA-expressing B cells.
Collapse
Affiliation(s)
- Alfur Fu-Hsin Hung
- Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, Taiwan
| | | | | | | | | | | |
Collapse
|
38
|
Wan L, Chen JB, Chen HH, Huang J, Yu HM, Luo SF, Tsai FJ, Chang TW. Genetic variations in the C epsilon mX domain of human membrane-bound IgE. Immunogenetics 2010; 62:273-80. [PMID: 20333376 DOI: 10.1007/s00251-010-0437-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2010] [Accepted: 02/25/2010] [Indexed: 10/19/2022]
Abstract
The epsilon chain of membrane-bound IgE (mIgE) is expressed predominantly as a "long" isoform, containing an extra segment of 52 amino acid (a.a.) residues, referred to as C epsilon mX, between the CH4 domain and the C-terminal membrane-anchoring transmembrane peptide. C epsilon mX results from an alternative splicing of the epsilon RNA transcript at 156-bp upstream of the splicing acceptor site used by the "short" isoform. Here, based on an analysis of the C epsilon mX genomic DNA sequences of 320 subjects residing in Taiwan, we report that single-nucleotide polymorphisms have been found at two positions, namely, G/T at #46 and A/G at #93 (along the 156 bp of C epsilon mX), with the former creating an amino acid change from Val to Leu at #16 (along the 52 a.a. of C epsilon mX) and the latter resulting in no change (Gly). Among the 640 C epsilon mX sequences identified, the previously known 46G93A allelic form appeared 293 times, the newly discovered 46T93A allelic form (GeneBank accession no. GU208817) 26 times, and the 46G93G allelic form (GU208818) 321 times. No 46T93G allelic form was found. Serum IgE measurements showed that the polymorphisms did not correlate with the levels of serum IgE. The anti-C epsilon mX monoclonal antibody, 4B12, could bind equally well to mIgE.Fc(L)(16V) and mIgE.Fc(L)(16L). While genetic variation of C epsilon mX of broader populations should also be investigated, these newly discovered genetic variants of C epsilon mX in the Taiwanese population do not seem to affect the feasibility of using an anti-C epsilon mX mAb, such as 4B12, to target mIgE-expressing B cells.
Collapse
Affiliation(s)
- Lei Wan
- Genetic Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung, 40447, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|